nach oben

Supportive Care in Cancer

Erschienen in:

23.02.2020 | Review Article

Prognostic value of sarcopenia in survivors of hematological malignances undergoing a hematopoietic stem cell transplantation: a systematic review and meta-analysis

verfasst von: Shuli Jia, Runjuan Qiao, Yuting Xiao, Dan Qin, Wanyu Zhao, Yunli Zhao, Xiaolei Liu, Birong Dong

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Sarcopenia is increasingly recognized as an independent risk factor for poor outcomes in patients undergoing hematopoietic stem cell transplantation (HSCT), and it is a potentially modifiable factor. The purpose of the present systematic review and meta-analysis is to summarize and integrate current evidence in this field.

Methods

We searched EMBASE, MEDLINE, and Cochrane DSR through Ovid and PubMed websites to identify relevant studies. Studies evaluated sarcopenia before HSCT and reported associations between sarcopenia and post-transplant outcomes were included. Two authors independently applied eligibility criteria, assessed quality, and extracted data. Odds ratio (OR) and their 95% confidence intervals (CIs) were pooled to examine the association between sarcopenia and post-transplant outcomes by using the review manager 5.3 software.

Results

Seven retrospective cohort studies met our inclusion criteria. The overall quality of studies was low to moderate. Sarcopenia was associated with higher non-relapse mortality [odds ratio (OR) 1.97; 95% CI 1.45, 2.68; P < 0.0001; I² = 0%] and shorter overall survival [odds ratio (OR) 0.44; 95% CI 0.26, 0.75; P = 0.002; I² = 65%] in patients undergoing HSCT.

Conclusions

Clinicians could use sarcopenia to balance the risks and benefits of transplantation as early as possible; in addition, interventions can be used to prevent sarcopenia and improve physical function and quality of life. Well-designed, prospective, and large-scale clinical studies are needed to consolidate the evidence.

Nur mit Berechtigung zugänglich

Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G, Einsele H, Gaspar HB, Gratwohl A, Passweg J, Peters C, Rocha V, Saccardi R, Schouten H, Sureda A, Tichelli A, Velardi A, Niederwieser D, European Group for Blood and Marrow Transplantation (2010) Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 45(2):219–234. https://doi.org/10.1038/bmt.2009.141 CrossRefPubMed

Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte RF, Dufour C, Kuball J, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Nagler A, Sureda A, Mohty M (2016) Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant 51(6):786–792. https://doi.org/10.1038/bmt.2016.20 CrossRefPubMedPubMedCentral

Appelbaum FR (2008) What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)? Best Pract Res Clin Haematol 21(4):667–675. https://doi.org/10.1016/j.beha.2008.06.005 CrossRefPubMedPubMedCentral

Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, Sandmaier B (2009) Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(3):367–369. https://doi.org/10.1016/j.bbmt.2008.12.497 CrossRef

Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, Sorror ML, Horowitz MM, Bolwell B, Rizzo JD, Socié G (2011) Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 29(16):2230–2239. https://doi.org/10.1200/JCO.2010.33.7212 CrossRefPubMedPubMedCentral

Ashton LJ, Le Marsney RE, Dodds AJ, Nivison-Smith I, Wilcox L, O'Brien TA et al (2014) A population-based cohort study of late mortality in adult autologous hematopoietic stem cell transplant recipients in Australia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 20(7):937–945. https://doi.org/10.1016/j.bbmt.2014.03.006 CrossRef

Styczynski J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S et al (2019) Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplant 55:126–136. https://doi.org/10.1038/s41409-019-0624-z CrossRefPubMedPubMedCentral

Cho SK, McCombs J, Punwani N, Lam J (2019) Complications and hospital costs during hematopoietic stem cell transplantation for non-Hodgkin lymphoma in the United States. Leuk Lymphoma:1–7. https://doi.org/10.1080/10428194.2019.1581932

Rivera-Franco MM, Leon-Rodriguez E, Castro-Saldana HL (2017) Costs of hematopoietic stem cell transplantation in a developing country. Int J Hematol 106(4):573–580. https://doi.org/10.1007/s12185-017-2278-1 CrossRefPubMed

10.

Wais V, Bunjes D, Kuchenbauer F, Sorror ML (2018) Comorbidities, age, and other patient-related predictors of allogeneic hematopoietic cell transplantation outcomes. Expert Rev Hematol 11(10):805–816. https://doi.org/10.1080/17474086.2018.1509703 CrossRefPubMed

11.

Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, Guralnik J et al (2018) International Clinical Practice Guidelines for Sarcopenia (ICFSR): screening, diagnosis and management. The journal of nutrition, health & aging 22(10):1148–1161. https://doi.org/10.1007/s12603-018-1139-9 CrossRef

12.

Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age and ageing 48(1):16–31. https://doi.org/10.1093/ageing/afy169.

13.

Daly LE, Ryan AM, Power DG (2016) Response to “Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer”. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34(31):3816–3817. https://doi.org/10.1200/jco.2016.68.8010 CrossRef

14.

Nakamura N, Hara T, Shibata Y, Matsumoto T, Nakamura H, Ninomiya S, Kito Y, Kitagawa J, Kanemura N, Goto N, Shiraki M, Miyazaki T, Takeuchi T, Shimizu M, Tsurumi H (2015) Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma. Ann Hematol 94(12):2043–2053. https://doi.org/10.1007/s00277-015-2499-4 CrossRefPubMed

15.

Yang M, Shen Y, Tan L, Li W (2019) Prognostic value of sarcopenia in lung cancer: a systematic review and meta-analysis. Chest. 156(1):101–111. https://doi.org/10.1016/j.chest.2019.04.115 CrossRefPubMed

16.

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62(10):1006–1012. https://doi.org/10.1016/j.jclinepi.2009.06.005 CrossRefPubMed

17.

Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2011

18.

Lo CK, Mertz D, Loeb M (2014) Newcastle-Ottawa scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol 14:45. https://doi.org/10.1186/1471-2288-14-45 CrossRefPubMedPubMedCentral

19.

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ (Clinical research ed) 327(7414):557–560. https://doi.org/10.1136/bmj.327.7414.557 CrossRef

20.

Ando T, Fujisawa S, Sakuma T, Teshigawara H, Matsumura A, Suzuki T et al (2017) Value of computed tomography-defined sarcopenia: a prognostic predictor of non-relapse mortality following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome. Blood 130(Supplement 1):4562–. https://doi.org/10.1182/blood.V130.Suppl_1.4562.4562.

21.

Armenian SH, Xiao M, Berano Teh J, Lee B, Chang HA, Mascarenhas K et al (2019) Impact of sarcopenia on adverse outcomes after allogeneic hematopoietic cell transplantation. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djy231

22.

Caram MV, Bellile EL, Englesbe MJ, Terjimanian M, Wang SC, Griggs JJ, Couriel D (2015) Sarcopenia is associated with autologous transplant-related outcomes in patients with lymphoma. Leuk Lymphoma 56(10):2855–2862. https://doi.org/10.3109/10428194.2015.1014359 CrossRefPubMed

23.

DeFilipp Z, Troschel FM, Qualls DA, Li S, Kuklinski MW, Kempner ME et al (2018) Evolution of body composition following autologous and allogeneic hematopoietic cell transplantation: incidence of sarcopenia and association with clinical outcomes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 24(8):1741–1747. https://doi.org/10.1016/j.bbmt.2018.02.016 CrossRef

24.

Kim SJ, Kim Y, Hwang DY, Hyun SY, Jang JE, Lee JY et al (2013) Low psoas muscle/BMI ratio is a bad prognostic index of non-relapse survival after allogeneic stem cell transplantation. Blood Conference: 55th Annual Meeting of the American Society of Hematology, ASH 122:21

25.

Kurosawa S, Takeuchi Y, Matsui M, Tsukada M, Iwama K, Yamada K et al (2018) Clinical impact of pre-transplant intramuscular adipose tissue content on outcome of cord blood transplantation. Blood 132(Suppl. 1). https://doi.org/10.1182/blood-2018-99-110691.

26.

Neto AC, Del Guerra Carvalho Moraes B, Rocha IMG, Bezerra FA, Medeiros GOC, Alves LBO et al (2018) Association of sarcopenia with toxicities and survival after autologous hematopoietic stem cell transplantation for adults with lymphomas. Blood 132(Suppl. 1). https://doi.org/10.1182/blood-2018-99-117717.

27.

Lindstrom I, Protto S, Khan N, Sillanpaa N, Hernesniemi J, Oksala N (2019) Developing sarcopenia predicts long-term mortality after elective endovascular aortic aneurysm repair. J Vasc Surg. https://doi.org/10.1016/j.jvs.2019.05.060

28.

Jones SE, Maddocks M, Kon SS, Canavan JL, Nolan CM, Clark AL, Polkey MI, Man WD (2015) Sarcopenia in COPD: prevalence, clinical correlates and response to pulmonary rehabilitation. Thorax 70(3):213–218. https://doi.org/10.1136/thoraxjnl-2014-206440 CrossRefPubMed

29.

Nakashima Y, Saeki H, Nakanishi R, Sugiyama M, Kurashige J, Oki E, Maehara Y (2018) Assessment of sarcopenia as a predictor of poor outcomes after esophagectomy in elderly patients with esophageal Cancer. Ann Surg 267(6):1100–1104. https://doi.org/10.1097/sla.0000000000002252 CrossRefPubMed

30.

Yumioka T, Honda M, Nishikawa R, Teraoka S, Kimura Y, Iwamoto H, Morizane S, Hikita K, Takenaka A (2019) Sarcopenia as a significant predictive factor of neutropenia and overall survival in urothelial carcinoma patients underwent gemcitabine and cisplatin or carboplatin. Int J Clin Oncol 25:158–164. https://doi.org/10.1007/s10147-019-01544-5 CrossRefPubMed

31.

Naumann P, Eberlein J, Farnia B, Hackert T, Debus J, Combs SE (2019) Continued weight loss and sarcopenia predict poor outcomes in locally advanced pancreatic cancer treated with chemoradiation. Cancers 11:5. https://doi.org/10.3390/cancers11050709 CrossRef

32.

Argiles JM, Busquets S, Felipe A, Lopez-Soriano FJ (2005) Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Int J Biochem Cell Biol 37(5):1084–1104. https://doi.org/10.1016/j.biocel.2004.10.003 CrossRefPubMed

33.

Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, Abellan van Kan G, Andrieu S, Bauer J, Breuille D, Cederholm T, Chandler J, de Meynard C, Donini L, Harris T, Kannt A, Keime Guibert F, onder G, Papanicolaou D, Rolland Y, Rooks D, Sieber C, Souhami E, Verlaan S, Zamboni M (2011) Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 12(4):249–256. https://doi.org/10.1016/j.jamda.2011.01.003 CrossRefPubMed

34.

Pamoukdjian F, Bouillet T, Levy V, Soussan M, Zelek L, Paillaud E (2018) Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: a systematic review. Clinical nutrition (Edinburgh, Scotland) 37(4):1101–1113. https://doi.org/10.1016/j.clnu.2017.07.010 CrossRef

35.

Han X, Kilfoy B, Zheng T, Holford TR, Zhu C, Zhu Y, Zhang Y (2008) Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. Cancer causes & control : CCC 19(8):841–858. https://doi.org/10.1007/s10552-008-9147-4 CrossRefPubMed

36.

Lee K, Shin Y, Huh J, Sung YS, Lee IS, Yoon KH, Kim KW (2019) Recent issues on body composition imaging for sarcopenia evaluation. Korean J Radiol 20(2):205–217. https://doi.org/10.3348/kjr.2018.0479 CrossRefPubMed

37.

Prado CM, Birdsell LA, Baracos VE (2009) The emerging role of computerized tomography in assessing cancer cachexia. Current opinion in supportive and palliative care 3(4):269–275. https://doi.org/10.1097/SPC.0b013e328331124a CrossRefPubMed

38.

Nishimura JM, Ansari AZ, D'Souza DM, Moffatt-Bruce SD, Merritt RE, Kneuertz PJ (2019) Computed tomography-assessed skeletal muscle mass as a predictor of outcomes in lung cancer surgery. Ann Thorac Surg. https://doi.org/10.1016/j.athoracsur.2019.04.090

39.

Elsawy M, Sorror ML (2016) Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 51(10):1283–1300. https://doi.org/10.1038/bmt.2016.141 CrossRefPubMed

40.

Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS et al (2014) Sarcopenia in Asia: Consensus report of the Asian working group for sarcopenia. J Am Med Dir Assoc 15(2):95–101. https://doi.org/10.1016/j.jamda.2013.11.025.

41.

Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, et al (2011) Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. Journal of the American Medical Directors Association 12(4):249–56. https://doi.org/10.1016/j.jamda.2011.01.003.

42.

Gerrie AS, Plantinga P, Nishikawa K, Hung S, Kadgien J, Chernoff B et al (2016) Implementation of a physician-prescribed exercise program as standard of care in allogeneic stem cell transplant (SCT) patients (pts) in British Columbia: a pilot study. Blood 128:22CrossRef

43.

Gevedon AJ, Monfreda JK (2014) Physical therapy during the hemopoietic stem cell transplant process to improve quality of life. Biol Blood Marrow Transplan 1:S198CrossRef

44.

van der Meij BS, De Groot LM, Deutz NEP, Engelen M (2019) Effects of acute oral feeding on protein metabolism and muscle protein synthesis in individuals with cancer. Nutrition (Burbank, Los Angeles County, Calif) 110531:67–68. https://doi.org/10.1016/j.nut.2019.06.012 CrossRef

45.

Takekiyo T, Dozono K, Mitsuishi T, Murayama Y, Maeda A, Nakano N, Kubota A, Tokunaga M, Takeuchi S, Takatsuka Y, Utsunomiya A (2015) Effect of exercise therapy on muscle mass and physical functioning in patients undergoing allogeneic hematopoietic stem cell transplantation. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 23(4):985–992CrossRef

Titel: Prognostic value of sarcopenia in survivors of hematological malignances undergoing a hematopoietic stem cell transplantation: a systematic review and meta-analysis
verfasst von: Shuli Jia
Runjuan Qiao
Yuting Xiao
Dan Qin
Wanyu Zhao
Yunli Zhao
Xiaolei Liu
Birong Dong
Publikationsdatum: 23.02.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 8/2020
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-020-05359-3

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Prognostic value of sarcopenia in survivors of hematological malignances undergoing a hematopoietic stem cell transplantation: a systematic review and meta-analysis

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2020

Effect of cryotherapy on dose of adjuvant paclitaxel in early-stage breast cancer

Cannabis use in pediatric cancer patients: what are they reading? A review of the online literature

Cancer survivorship care during COVID-19—perspectives and recommendations from the MASCC survivorship study group

Pilot study of a telehealth perioperative physical activity intervention for older adults with cancer and their caregivers

Safety and feasibility of inspiratory muscle training for hospitalized patients undergoing hematopoietic stem cell transplantation: a randomized controlled study

Effects of ginger adjunct to the standard prophylaxis on reducing carboplatin and paclitaxel-induced nausea vomiting: a randomized controlled study

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie